Cargando…

Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population

The fibrosis-4 (FIB-4) index is the most widely used estimated formula to screen for advanced hepatic fibrosis; however, it has a considerable intermediate zone. Here, we propose an algorithm to reduce the intermediate zone and improve the diagnostic performance of screening for advanced liver fibro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Mimi, Jun, Dae Won, Park, Huiyul, Kang, Bo-Kyeong, Sumida, Yoshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230806/ https://www.ncbi.nlm.nih.gov/pubmed/32295166 http://dx.doi.org/10.3390/jcm9041119

Ejemplares similares

Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center
por: Roh, Yun Hwa, et al.
Publicado: (2021)

Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population
por: Park, Huiyul, et al.
Publicado: (2022)

Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B
por: Bui, Hoang Huu, et al.
Publicado: (2023)

Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes
por: Park, Huiyul, et al.
Publicado: (2020)

Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C
por: Xu, Hongqin, et al.
Publicado: (2017)

M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals
por: Saleh, Shereen A, et al.
Publicado: (2020)

Diagnostic performance of Mac‐2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups
por: Nah, Eun‐Hee, et al.
Publicado: (2020)

Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C
por: Takakusagi, Satoshi, et al.
Publicado: (2021)

Selecting the Target Population for Screening of Hepatic Fibrosis in Primary Care Centers in Korea
por: Park, Huiyul, et al.
Publicado: (2022)

FIB-5 versus FIB-4 index for assessment of hepatic fibrosis in chronic hepatitis B affected patients
por: Metwally, Khaled, et al.
Publicado: (2020)

Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi
por: Baudi, Ian, et al.
Publicado: (2020)

Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection
por: Mak, Lung-Yi, et al.
Publicado: (2018)

Diagnostic performance of the fibrosis-4 index and the NAFLD fibrosis score for screening at-risk individuals in a health check-up setting
por: Park, Huiyul, et al.
Publicado: (2023)

Galectin-9 in autoimmune hepatitis: Correlation between serum levels of galectin-9 and M2BPGi in patients with autoimmune hepatitis
por: Matsuoka, Naoki, et al.
Publicado: (2019)

Diagnostic value of FIB-4 for liver fibrosis in patients with hepatitis B: a meta-analysis of diagnostic test
por: Yin, Zhi, et al.
Publicado: (2017)

Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients
por: Liu, Jessica, et al.
Publicado: (2017)

The Diagnostic Value of the FIB-4 Index for Staging Hepatitis B-Related Fibrosis: A Meta-Analysis
por: Li, Yuanyuan, et al.
Publicado: (2014)

Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis
por: Migita, Kiyoshi, et al.
Publicado: (2018)

Significant Correlation Between Grip Strength and m2bpgi in Patients with Chronic Liver Diseases
por: Nishikawa, Hiroki, et al.
Publicado: (2019)

Mac-2 binding protein glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa
por: Vincent, Jeanne Perpétue, et al.
Publicado: (2022)

Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B
por: Li, Qiang, et al.
Publicado: (2017)

Diagnostic Accuracy of FIB-4 and FIB-5 Scores as Compared to Fibroscan for Assessment of Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease
por: Kumari, Bandana, et al.
Publicado: (2021)

Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver
por: Park, Huiyul, et al.
Publicado: (2021)

Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease
por: Park, Huiyul, et al.
Publicado: (2023)

Biological variation and reference change values of serum Mac‐2–binding protein glycosylation isomer (M2BPGi)
por: Choi, Rihwa, et al.
Publicado: (2022)

Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C
por: Takemura, Kazuya, et al.
Publicado: (2020)

The liver fibrosis index is superior to the APRI and FIB-4 for predicting liver fibrosis in chronic hepatitis B patients in China
por: Huang, Dedong, et al.
Publicado: (2019)

Substantial concordance between transient elastography and APRI and FIB-4 combination amongst hepatitis C inmates with non advanced liver fibrosis
por: Yela, E, et al.
Publicado: (2022)

Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon‐α treatment in HBeAg‐positive chronic hepatitis B patients
por: Zhu, Ming‐Yu, et al.
Publicado: (2018)

APRI and FIB-4 indices as diagnostic noninvasive scores for prediction of severe fibrosis in patients with biliary atresia
por: Nagi, Salma Abdel Megeed, et al.
Publicado: (2023)

APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level
por: Yen, Yi-Hao, et al.
Publicado: (2018)

Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community
por: Cheng, Pin-Nan, et al.
Publicado: (2018)

FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic
por: Sumida, Yoshio, et al.
Publicado: (2021)

Association of soluble T cell immunoglobulin domain and mucin-3 (sTIM-3) and mac-2 binding protein glycosylation isomer (M2BPGi) in patients with autoimmune hepatitis
por: Migita, Kiyoshi, et al.
Publicado: (2020)

Progressive changes in platelet counts and Fib-4 scores precede the diagnosis of advanced fibrosis in NASH patients
por: Zijlstra, Michael K, et al.
Publicado: (2023)

FIB nanostructures
por: Wang, Zhiming M
Publicado: (2013)

Liver Fibrosis Index FIB‐4 Is Associated With Mortality in COVID‐19
por: Li, Yijia, et al.
Publicado: (2020)

Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting
por: Blanco-Grau, Albert, et al.
Publicado: (2021)

Comparing Xe(+)pFIB and Ga(+)FIB for TEM sample preparation of Al alloys: Minimising FIB‐induced artefacts
por: Zhong, Xiangli, et al.
Publicado: (2020)

Advantages of a Novel Model for Predicting Hepatic Fibrosis in Chronic Hepatitis B Virus Carriers Compared with APRI and FIB-4 Scores
por: Kang, Na-Ling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n484mgt8h65j71njqi9stiul16